This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Vascular Effects of Sertraline in Heart Failure

This study has been terminated.
(PI change in institution)
Information provided by:
Yale University Identifier:
First received: December 22, 2007
Last updated: July 22, 2009
Last verified: July 2009
To determine the effects of chronic sertraline treatment on brachial artery flow-mediated dilation in patients with chronic heart failure and depression

Condition Intervention
Heart Failure Depression Drug: sertraline

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effects of Chronic Sertraline Hydrochloride Administration on Vascular Endothelial and Autonomic Function in Patients With Chronic Heart Failure

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Brachial artery flow-mediated dilation [ Time Frame: 2 months ]

Biospecimen Retention:   Samples Without DNA
Plasma and serum

Enrollment: 4
Study Start Date: January 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Chronic heart failure patients with concomitant depression
Drug: sertraline
open label 25-50 mg daily as tolerated


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
chronic heart failure patients with concomitant depression

Inclusion Criteria:

  • Chronic heart failure with LVEF<40%, age >21 years
  • Depression requiring medical treatment with sertraline

Exclusion Criteria:

  • Known intolerance of sertraline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00585455

United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Sponsors and Collaborators
Yale University
Principal Investigator: Stuart Katz, MD Yale School of Medicine
  More Information

Responsible Party: Stuart Katz, Yale University School of Medicine Identifier: NCT00585455     History of Changes
Other Study ID Numbers: 0410027131
Study First Received: December 22, 2007
Last Updated: July 22, 2009

Keywords provided by Yale University:
vascular endothelium
nitric oxide
heart failure
vascular biology

Additional relevant MeSH terms:
Heart Failure
Behavioral Symptoms
Heart Diseases
Cardiovascular Diseases
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs processed this record on August 18, 2017